PART I When used in this report, unless otherwise indicated, Nurix, Company, we, us and our refers to Nurix Therapeutics, Inc. and its wholly owned subsidiaries. Overview We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully artificial intelligence ...
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-01-28 | 2025-11-30 | 0001549595-26-000016 | EDGAR | 116K words |
| 2025-01-28 | 2024-11-30 | 0001549595-25-000016 | EDGAR | — |
| 2024-02-15 | 2023-11-30 | 0001549595-24-000025 | EDGAR | — |
| 2023-02-09 | 2022-11-30 | 0001549595-23-000021 | EDGAR | — |
| 2022-01-28 | 2021-11-30 | 0001564590-22-003007 | EDGAR | — |
| 2021-02-16 | 2020-11-30 | 0001564590-21-006071 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-09 | 2025-08-31 | 0001549595-25-000113 | EDGAR | 75K words |
| 2025-07-09 | 2025-05-31 | 0001549595-25-000095 | EDGAR | — |
| 2025-04-08 | 2025-02-28 | 0001549595-25-000055 | EDGAR | — |
| 2024-10-11 | 2024-08-31 | 0001549595-24-000131 | EDGAR | — |
| 2024-07-11 | 2024-05-31 | 0001549595-24-000098 | EDGAR | — |
| 2024-04-10 | 2024-02-29 | 0001549595-24-000049 | EDGAR | — |
| 2023-10-12 | 2023-08-31 | 0001549595-23-000048 | EDGAR | — |
| 2023-07-13 | 2023-05-31 | 0001549595-23-000040 | EDGAR | — |
| 2023-04-13 | 2023-02-28 | 0001549595-23-000032 | EDGAR | — |
| 2022-10-06 | 2022-08-31 | 0001564590-22-033709 | EDGAR | — |
| 2022-07-07 | 2022-05-31 | 0001564590-22-025450 | EDGAR | — |
| 2022-04-08 | 2022-02-28 | 0001564590-22-013988 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-06 | 0001193125-26-096734 | EDGAR | 1K words |
| 2026-01-28 | 0001549595-26-000013 | EDGAR | — |
| 2026-01-12 | 0001549595-26-000003 | EDGAR | — |
| 2025-12-09 | 0001549595-25-000121 | EDGAR | — |
| 2025-11-10 | 0001549595-25-000117 | EDGAR | — |
| 2025-10-22 | 0001193125-25-246964 | EDGAR | — |
| 2025-10-22 | 0001549595-25-000115 | EDGAR | — |
| 2025-10-09 | 0001549595-25-000112 | EDGAR | — |
| 2025-09-03 | 0001549595-25-000108 | EDGAR | — |
| 2025-08-22 | 0001549595-25-000105 | EDGAR | — |
113 total filings indexed. 85 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001549595 |
| Ticker | NRIX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nurixtx.com |
| Listed | 2020-07-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report